Stay Ahead of ASCO 2026: See What Gynecologic Oncologists Are Prioritizing

As the oncology community prepares to convene in Chicago for the 2026 ASCO Annual Meeting, OncLive® asked gynecologic oncology experts to identify the presentations they anticipate will drive discussion, inform practice, and spotlight emerging advances in the treatment of patients with gynecologic cancers.

“This year’s ASCO meeting will continue to build on the field’s momentum by expanding on novel treatment approaches for challenging cancer treatment scenarios. We will see ongoing updates on established trials, novel treatment paradigms, and a slew of early-phase data that could lead to the next big breakthrough,” Eric Rios-Doria, MD, said.

“It’s a very exciting time in the research arena in gynecologic malignancies, and I would encourage [my colleagues] to listen to the presentations, to read the abstracts once available, and then ultimately the peer-reviewed publications that result,” Maurie Markman, MD, said.

This exclusive preview features insights from:

• Eric Rios-Doria, MD, a gynecologic oncology fellow at the University of Washington Medicine in Seattle.
• Maurie Markman, MD, Editor-in-Chief of OncologyLive® and President of Medicine & Science, City of Hope Cancer Centers Atlanta, Chicago and Phoenix.

“Across gynecologic oncology, the integration of immunotherapy, antibody-drug conjugates [ADCs], targeted therapies, and biomarker-driven treatment strategies continues to rapidly reshape standards of care and redefine expectations for patient outcomes. As translational science and clinical trial design continue to evolve in parallel, this year’s ASCO meeting promises to provide an important glimpse into the next era of precision medicine in gynecologic cancer care,” Rios-Doria added.

Abstract 5501: Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/ GOG-3031/RUBY trial

Presentation time: May 29, 2:45-2:57 PM CT

Location: S100bc

Rios-Doria: “The RUBY trial [NCT03981796] was transformative for the treatment of patients with advanced and metastatic endometrial cancer. This is especially true for patients with mismatch repair–deficient/microsatellite instability–high [dMMR/MSI-H] status, who demonstrated dramatic improvements in progression-free survival [PFS] and OS with the addition of dostarlimab to carboplatin/paclitaxel. This new abstract is exciting because it moves beyond the initial response and explores “cure modeling,” which may identify a subgroup of patients achieving long-term durable remission that may confer a cure––something historically rare in advanced endometrial cancer. The findings could also reshape how clinicians counsel patients, by having discussions shift from temporary control toward the possibility of sustained long-term survival.”

Abstract 5502: Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRGGY018 trial

Presentation time: May 29, 2:57-3:09 PM CT

Location: S100bc

Markman: “The first 2 abstracts that are being presented in the oral session are looking at long-term survival results for 2 phase 3 randomized trials in endometrial cancer with checkpoint inhibitors. One is with dostarlimab-gxly [Jemperli] and the second is with pembrolizumab [Keytruda]. The drugs are now approved. Those will be very interesting abstracts.”

Rios-Doria: “The NRG-GY018 trial [NCT03914612] was practice-changing after showing a significant benefit in PFS with the addition of pembrolizumab to carboplatin/paclitaxel, particularly in the dMMR tumor population. [It also showed] meaningful activity in the [mismatch repair–proficient] population. This updated survival analysis is exciting, as the PFS improvements may translate into a true survival advantage, further solidifying chemoimmunotherapy as the standard of care in advanced and recurrent endometrial cancer. The study also includes subsequent therapies, which will help answer a key real-world clinical question: whether the survival benefit persists despite crossover or later-line immunotherapy. Together, these data may provide insight into long-term disease control and enhanced strategies for optimizing treatment sequencing strategies in endometrial cancer.”

Abstract 5503: Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOTOv10, LACOG-0223, and ANZGOG-2221/2023)

Presentation time: May 29, 3:33-3:45 PM CT

Location: S100bc

Markman: “We’re also going to see subgroup survival data from the ROSELLA trial [NCT05257408] which led to a new drug in platinum-resistant ovarian cancer. We know that the trial was positive from the point of view of overall survival [OS], but here we’re going to be looking at subgroup analyses, which should be very interesting.”

Rios-Doria: “ROSELLA has already shown that adding relacorilant [Lifyorli] to nab-paclitaxel [Abraxane] improved the outcomes that matter most in platinum-resistant ovarian cancer: PFS and OS, with reported median OS improving from 11.9 to 16.0 months and risk of death reduced by approximately 35%. A “prior taxane” subgroup analysis is intriguing, as the published ROSELLA trial reports that 73 of the 381 participants received taxane in the last regimen before the trial. If the benefit of relacorilant is preserved in heavily pretreated or recently taxane-exposed patients, it would represent a meaningful advancement for this patient population, which usually has limited treatment options.”

Abstract LBA5504: A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer

Presentation time: May 29, 3:45-3:57 PM CT

Location: S100bc

Markman: “There’s going to be a trial that evaluates a multi-kinase inhibitor with weekly paclitaxel in platinum-resistant ovarian cancer. It’s a phase 3 randomized trial [NCT04921527] being reported from investigators in China. Results of a phase 3 randomized trial with a novel drug should be very interesting.”

Rios-Doria: “This study explores expanding the current strategy of weekly paclitaxel in platinum-resistant or refractory ovarian cancer with the addition of chiauranib. This novel agent is mechanistically interesting because it is a multitarget inhibitor that simultaneously targets three key pathways involved in angiogenesis, mitosis, and the tumor microenvironment. In that context, the signal within a small phase 2 cohort of chiauranib with weekly paclitaxel produced an overall response rate of 53.4% and a median PFS of 5.6 months. This exciting trial builds on recent platinum-resistant studies in which a biologically rational partner is added to an established chemotherapy backbone.”

Abstract 5506: A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGOOVAR 2.34)

Presentation time: May 29, 4:33-4:45 PM CT

Location: S100bc

Markman: “Mirvetuximab soravtansine-gynx [Elahere] is FDA approved now in platinum-resistant ovarian cancer. A randomized phase 2 trial [NCT04274426] is looking at patients who are stated to have been eligible for platinum agents. So presumably this is going to be in the recurrent platinum-sensitive setting. It should be very interesting to see what the use of mirvetuximab compared with the control arm will show. Multiple phase 1/2 trials are being presented with a variety of drugs and targets, specifically ADCs. We now have several of these [agents] that are approved for use in gynecologic cancers. This is a very exciting area of development, with very exciting targets, very exciting payloads, and antibodies that are being looked at. It will be very interesting to see what the early results or the earlier results show in terms of both safety and efficacy.”

Rios-Doria: “This study is exciting as it seeks to answer a key clinical question of whether a FRα-targeted ADC can become a new platinum partner for recurrent platinum-sensitive disease when reuse of bevacizumab [Avastin] is not feasible or desirable. Mirvetuximab soravtansine has already shown activity in FRα-selected ovarian cancer, in particular within the platinum-resistant disease setting. Early-phase studies using combination therapy with carboplatin in the platinum-sensitive setting suggested substantial activity, providing a rationale for further formal testing using this combination. If positive, MIROVA/AGO-OVAR 2.34 could expand mirvetuximab from a later-line biomarker-selected option into an earlier recurrent-disease strategy and help define a new chemotherapy backbone for FRα-high (>75%) disease.”